
Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: [year=2009; month=4; day=18; hr=17; min=48; sec=44; ms=450;]

Validated By CRFValidator v 1.0.3

Application No: 10562486 Version No: 3.0

Input Set:

Output Set:

Started: 2009-04-03 09:51:17.481 **Finished:** 2009-04-03 09:51:19.129

Elapsed: 0 hr(s) 0 min(s) 1 sec(s) 648 ms

Total Warnings: 21
Total Errors: 0

No. of SeqIDs Defined: 22
Actual SeqID Count: 22

Error code		Error Descript	ion								
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(2)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(3)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(4)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(5)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(6)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(7)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(8)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(9)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(10)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(11)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(12)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(13)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(14)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(15)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(16)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(17)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(18)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(19)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(20)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(21)

Input Set:

Output Set:

Started: 2009-04-03 09:51:17.481 **Finished:** 2009-04-03 09:51:19.129

Elapsed: 0 hr(s) 0 min(s) 1 sec(s) 648 ms

Total Warnings: 21
Total Errors: 0
No. of SeqIDs Defined: 22

Actual SeqID Count: 22

Error code Error Description

This error has occured more than 20 times, will not be displayed

SEQUENCE LISTING

```
<110> Sugiyama, Haruo
<120> Method of selecting patients suitable for WT1 vaccine
<130> 664590
<140> 10562486
<141> 2005-12-27
<150> PCT/JP2004/009378
<151> 2004-06-25
<150> JP 2003-184436
<151> 2003-06-27
<150> JP 2004-070497
<151> 2004-03-12
<160> 22
<170> PatentIn Ver. 2.1
<210> 1
<211> 449
<212> PRT
<213> Homo sapiens
<400> 1
Met Gly Ser Asp Val Arg Asp Leu Asn Ala Leu Leu Pro Ala Val Pro
                                   10
Ser Leu Gly Gly Gly Gly Cys Ala Leu Pro Val Ser Gly Ala Ala
            20
                                25
Gln Trp Ala Pro Val Leu Asp Phe Ala Pro Pro Gly Ala Ser Ala Tyr
                            40
Gly Ser Leu Gly Gly Pro Ala Pro Pro Pro Ala Pro Pro Pro Pro
     50
                       55
                                           60
Pro Pro Pro Pro His Ser Phe Ile Lys Gln Glu Pro Ser Trp Gly Gly
Ala Glu Pro His Glu Glu Gln Cys Leu Ser Ala Phe Thr Val His Phe
               85
                                  90
Ser Gly Gln Phe Thr Gly Thr Ala Gly Ala Cys Arg Tyr Gly Pro Phe
           100
                               105
Gly Pro Pro Pro Pro Ser Gln Ala Ser Ser Gly Gln Ala Arg Met Phe
       115
                           120
```

Pro Asn Ala Pro Tyr Leu Pro Ser Cys Leu Glu Ser Gln Pro Ala Ile

135 140

Arg Asn Gln Gly Tyr Ser Thr Val Thr Phe Asp Gly Thr Pro Ser Tyr Gly His Thr Pro Ser His His Ala Ala Gln Phe Pro Asn His Ser Phe Lys His Glu Asp Pro Met Gly Gln Gln Gly Ser Leu Gly Glu Gln Gln Tyr Ser Val Pro Pro Pro Val Tyr Gly Cys His Thr Pro Thr Asp Ser Cys Thr Gly Ser Gln Ala Leu Leu Leu Arg Thr Pro Tyr Ser Ser Asp Asn Leu Tyr Gln Met Thr Ser Gln Leu Glu Cys Met Thr Trp Asn Gln Met Asn Leu Gly Ala Thr Leu Lys Gly Val Ala Ala Gly Ser Ser Ser Ser Val Lys Trp Thr Glu Gly Gln Ser Asn His Ser Thr Gly Tyr Glu Ser Asp Asn His Thr Thr Pro Ile Leu Cys Gly Ala Gln Tyr Arg Ile His Thr His Gly Val Phe Arg Gly Ile Gln Asp Val Arg Arg Val Pro Gly Val Ala Pro Thr Leu Val Arg Ser Ala Ser Glu Thr Ser Glu Lys Arg Pro Phe Met Cys Ala Tyr Pro Gly Cys Asn Lys Arg Tyr Phe Lys Leu Ser His Leu Gln Met His Ser Arg Lys His Thr Gly Glu Lys Pro Tyr Gln Cys Asp Phe Lys Asp Cys Glu Arg Arg Phe Ser Arg Ser Asp Gln Leu Lys Arg His Gln Arg Arg His Thr Gly Val Lys Pro Phe Gln Cys Lys Thr Cys Gln Arg Lys Phe Ser Arg Ser Asp His Leu Lys Thr His Thr Arg Thr His Thr Gly Lys Thr Ser Glu Lys Pro Phe Ser Cys Arg Trp Pro Ser Cys Gln Lys Lys Phe Ala Arg Ser Asp Glu Leu Val

Arg His His Asn Met His Gln Arg Asn Met Thr Lys Leu Gln Leu Ala

435 440 445

Leu

<210> 2 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 2 Cys Met Thr Trp Asn Gln Met Asn Leu <210> 3 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 3 Cys Tyr Thr Trp Asn Gln Met Asn Leu 1 <210> 4 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 4 Arg Met Phe Pro Asn Ala Pro Tyr Leu 1 <210> 5 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Synthetic Peptide <400> 5 Arg Tyr Pro Ser Cys Gln Lys Lys Phe

```
<210> 6
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthetic Peptide
<400> 6
Ser Tyr Thr Trp Asn Gln Met Asn Leu
<210> 7
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthetic Peptide
<400> 7
Ala Tyr Thr Trp Asn Gln Met Asn Leu
1
<210> 8
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthetic Peptide
<400> 8
Gly Tyr Thr Trp Asn Gln Met Asn Leu
 1
<210> 9
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthetic Peptide
<400> 9
Arg Tyr Thr Trp Asn Gln Met Asn Leu
<210> 10
<211> 9
<212> PRT
<213> Artificial Sequence
```

```
<220>
<223> Synthetic Peptide
<400> 10
Lys Tyr Thr Trp Asn Gln Met Asn Leu
<210> 11
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthetic Peptide
<400> 11
Arg Tyr Phe Pro Asn Ala Pro Tyr Leu
<210> 12
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthetic Peptide
<400> 12
Arg Tyr Pro Gly Val Ala Pro Thr Leu
1
<210> 13
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthetic Peptide
<400> 13
Ala Tyr Leu Pro Ala Val Pro Ser Leu
 1
<210> 14
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthetic Peptide
```

```
<400> 14
Asn Tyr Met Asn Leu Gly Ala Thr Leu
<210> 15
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthetic Peptide
<400> 15
Arg Val Pro Gly Val Ala Pro Thr Leu
      5
<210> 16
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthetic Peptide
<400> 16
Arg Tyr Pro Ser Ser Gln Lys Lys Phe
<210> 17
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthetic Peptide
<400> 17
Arg Tyr Pro Ser Ala Gln Lys Lys Phe
1
<210> 18
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthetic Peptide
<400> 18
Arg Tyr Pro Ser Gly Gln Lys Lys Phe
```

<210> 19	
<211> 40	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Synthetic DNA	
12237 Byncheele DNA	
<100× 10	
<400> 19	4.0
ccatgggcag ccattctatg cgctattttt ctacctccgt	40
<210> 20	
<211> 45	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Reverse Primer	
<400> 20	
ggatcctggc tcccatctca gggtgagggg cttgggcaga ccctc	45
<210> 21	
<211> 30	
<212> DNA	
<213> Artificial Sequence	
.000	
<220>	
<223> Synthetic DNA	
<400> 21	
catatgatcc agcgtacccc gaaaattcag	30
<210> 22	
<211> 30	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Reverse Primer	
<400> 22	
ggatccttac atgtctcgat cccacttaac	30
ggattettat atgittegat tecatettat	50